

-18-

We claim:

1. A composition that is suitable for administration to a human subject comprising an anti-A β antibody that is free of A β peptide or that has acceptably low levels thereof.
2. The composition of Claim 1 wherein said A β peptide is non-human A β peptide.
3. The composition of Claim 1 wherein said A β peptide is human A β peptide.
4. A composition that is suitable for administration to a human subject comprising an anti-A β antibody having an undetectable concentration of A β peptide.
5. The composition of any one of claims 1-4 wherein said anti-A β antibody is a humanized anti-A β antibody.
6. A pharmaceutical composition that comprises the antibody of any of claims 1-5 and a pharmaceutically acceptable excipient.
7. A process for preparing the anti-A β antibody of any of claims 1-5 comprising expressing the anti-A β antibody in an NS0, CHO, HEK 293, or PER.C6 cell line and purifying the anti-A β antibody.
8. A process according to claim 7, wherein the cell line is NS0.
9. A process according to claim 7, wherein the cell line is CHO.
10. A process for preparing the anti-A β antibody of any of claims 1-5 comprising culturing a cell line expressing the anti-A β antibody in a cell culture containing a β -secretase inhibitor and purifying the anti-A β antibody.

-19-

11. A process for preparing the anti-A β antibody of any of claims 1-5 comprising culturing a cell line expressing the anti-A β antibody in a cell culture containing a γ -secretase inhibitor and purifying the anti-A β antibody.
12. A process for preparing the anti-A β antibody of any of claims 1-5 comprising expressing the anti-A β antibody in a cell line that lacks amyloid precursor protein, β -secretase, or γ -secretase and purifying the anti-A β antibody.
13. A process according to claim 12 wherein the cell line lacks amyloid precursor protein.
14. A process according to claim 12 wherein the cell line lacks β -secretase.
15. A process according to claim 12 wherein the cell line lacks γ -secretase.